Furthering their expertise in the field of cannabinoid-based therapeutics, Zelira Therapeutics (ASX: ZLD) is set to tap into the oral care market with the launch of hemp derived toothpaste in the United States. 

The toothpaste formulation was created by Sprinjene CEO and Founder, Dr Sayed Abrahim who developed the oral care product which is gluten-free, vegan, halal and free of harsh chemicals. 

Under the partnership, Zelira will commercialise the Zelira-Sprinjene products which are currently manufactured in New Jersey. 

“Our products will be available for sale in the USA by Q4 2020 and we remain focused on unlocking the benefits of  cannabinoid-based applications as we expand our company’s reach into new and lucrative markets,” said Zelira USA Managing Director, Dr Oludare Odumosu.

“This will be the first Over-the-Counter (OTC) product line launched by Zelira.” 

The expansion into oral care products is a new venture for Zelira which has been focusing its efforts on medicinal cannabis as a treatment for insomnia and chronic pain. In the US, Zelira has already commercialised its HOPE brand of products as a treatment for autism and are generating revenue in the States of Louisiana and Pennsylvania. The HOPE products sold are the only two products that have been FDA approved as treatments for autism which affects 1.5% of children. 

Zelira has plans to launch HOPE in Australia before the end of 2020 where manufacturing and distribution partners have been secured but the products are still subject to regulatory approval. 

No commercial terms of the new Zelira-Sprinjene cannabinoid-based toothpaste were disclosed by the Company, or its specific health benefits.